Avant Immunotherapeutics gets $750,000 for Ty800 development

By Elaine Rigoli

Tampa, Fla., Sept. 27 - Avant Immunotherapeutics, Inc. has been awarded a phase 2 Small Business Innovation Research grant to support further development and manufacture of Ty800, the company's single dose, oral typhoid vaccine.

The National Institute of Allergy and Infectious Disease of the National Institutes of Health awarded this grant titled "Development and cGMP Manufacture of a Vitrified Typhoid Vaccine," which provides about $750,000 in funding to Avant.

The Needham, Mass.-based therapeutic development company said it will use the funds to move the Ty800 program forward using outside sources to help support the cost of Ty800 vaccine development.

The development of a safe and effective typhoid fever vaccine is important for protecting residents, travelers and military personnel from typhoid fever in endemic areas, officials noted.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.